Shares of Arbutus Biopharma slid after the company said the European Patent Office had revoked one of its patents. The stock slipped 12%, to $4.15, midday Friday, but has gained 29% in the past year.
HALIFAX, Canada--(BUSINESS WIRE)--Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today that the European Patent Office (EPO), Opposition Division, has ruled ...
Arbutus Biopharma Corporation stock fell 7% on Friday following news that the Board of Appeal of the European Patent Office ...
New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEGO, CALIFORNIA / ACCESS ...
The Enlarged Board of Appeal of the European Patent Office (EPO) has issued a new dual decision – G1/22 and G2/22 – dealing with the assessment of priority rights at the EPO. The decision represents a ...
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP ...
Article 83 of the European Patent Convention is the 'quiet clause' that can invalidate a patent for insufficient disclosure.
-- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI Delivered Via PARI’s Proprietary eFlow® Nebulizer System -- Savara Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback